Skip to main content
Midas Edge

Vera Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Class A Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balances as of December 31, 202571,267,429$71$1,364,529$786$(760,865)$604,521
Issuance of common stock pursuant to exercise of options155,63912,500——2,501
Issuance of common stock upon vesting of restricted stock units237,070—————
Issuance of common stock pursuant to employee stock purchase plan69,952—1,441——1,441
Stock-based compensation——13,208——13,208
Change in unrealized gains and losses on marketable securities———(942)—(942)
Net loss————(121,032)(121,032)
Balances as of March 31, 202671,730,090$72$1,381,678$(156)$(881,897)$499,697
Issuance of common stock pursuant to exercise of options166,995—1,918——1,918
Issuance of common stock upon vesting of restricted stock units58,800—————
Stock-based compensation——15,863——15,863
Change in unrealized gains and losses on marketable securities———(247)—(247)
Net loss————(109,473)(109,473)
Balances as of June 30, 202671,955,885$72$1,399,459$(403)$(991,370)$407,758
Issuance of common stock pursuant to exercise of options226,441—2,218——2,218
Issuance of common stock upon vesting of restricted stock units55,429—————
Issuance of common stock pursuant to employee stock purchase plan50,149—1,494——1,494
Stock-based compensation——15,728——15,728
Change in unrealized gains and losses on marketable securities———(301)—(301)
Net loss————(93,711)(93,711)
Balances as of September 30, 202672,287,904$72$1,418,899$(704)$(1,085,081)$333,186
Class A Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balances as of December 31, 202463,559,858$64$1,037,948$393$(461,250)$577,155
Issuance of common stock pursuant to exercise of options100,587—982——982
Issuance of common stock upon vesting of restricted stock units90,283—————
Issuance of common stock pursuant to employee stock purchase plan23,430—551——551
Stock-based compensation——7,744——7,744
Change in unrealized gains and losses on marketable securities———261—261
Net loss————(51,694)(51,694)
Balances as of March 31, 202563,774,158$64$1,047,225$654$(512,944)$534,999
Issuance of common stock pursuant to exercise of options45,162—464——464
Issuance of common stock upon vesting of restricted stock units4,345—————
Stock-based compensation——9,472——9,472
Change in unrealized gains and losses on marketable securities———(127)—(127)
Net loss————(76,531)(76,531)
Balances as of June 30, 202563,823,665$64$1,057,161$527$(589,475)$468,277
Issuance of common stock pursuant to exercise of options4,882—31——31
Issuance of common stock upon vesting of restricted stock units28,390—————
Issuance of common stock pursuant to employee stock purchase plan37,908—766——766
Stock-based compensation——9,745——9,745
Change in unrealized gains and losses on marketable securities———354—354
Net loss————(80,293)(80,293)
Balances as of September 30, 202563,894,845$64$1,067,703$881$(669,768)$398,880
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.